Therefore, the therapeutic ratio of selective PDE4 inhibitors for use in treating asthma and chronic obstructive pulmonary disease (COPD) is defined as the PDE4H/PDE4L ratio [17, 18]. Here, PDE4A is linked to chronic obstructive pulmonary disease.